Clinical trials: Metabolism and Excretion
Obesity, Edema
Effect of Body Weight Loading on Urinary Electrolyte Excretion
Title: Effect of body weight loading on urinary electrolyte excretion Swedish Title: Effekt av belastning på utsöndring av elektrolyter Study period: Q2-Q3 2017 Study site: The study will be performed at the Institution for…
- Trial name
- EBU (NCT03213717)
- Testing
- Heavy Casall HIT weight vest, Standing, Water load
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Göteborg University
Healthy Volunteer
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
This is a single-center, open label, multiple dose study to investigate the pharmacokinetics of RG1662 given twice daily over 28 days, and in addition, the excretion and metabolism of [13C]-labeled IV microdoses and an oral…
- Trial name
- NCT01684891
- Testing
- RG1662
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
- Trial name
- NCT02489513
- Testing
- [14C]-AG-120
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Gout, Hyperuricemia
Mass Balance Study of [14C]LC350189 in Healthy Volunteers
This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of [14C] radiolabeled LC350189 after oral administration.
- Trial name
- NCT04070846
- Testing
- [14C] LC350189
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy Male Subjects
Benznidazole Absorption, Metabolism and Excretion Study
This Phase I ADME study will be conducted to evaluate the pharmacokinetics of benznidazole.
- Trial name
- NCT03739541
- Testing
- [14C]-Benznidazole
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Exeltis France
Chronic Kidney Diseases, Magnetic Resonance Imaging
Material Balance Study of TQ-B3525
A clinical study to investigate the absorption, metabolism and excretion of [14C] TQ-B3525 in Chinese adult male healthy subjects, aiming to quantitatively analyze the total radioactivity in the excreta of male healthy subjects…
- Trial name
- NCT05675202
- Testing
- TQ-B3525
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
The purpose of this study is to assess the absorption, metabolism, and elimination of CC-90010 and its metabolites following a single oral dose of radiolabeled CC-90010 in participants with advanced solid tumors.
- Trial name
- NCT05678283
- Testing
- [14C]CC-90010, CC-90010
- Where
- Spain
- Sponsor
- Bristol-Myers Squibb
Healthy Male Subjects
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
This is an open-label, single-dose study in healthy male subjects to investigate the absorption, metabolism, and excretion (AME) of KW-6356.
- Trial name
- NCT04147910
- Testing
- KW-6356
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin, Inc.
Chronic Kidney Diseases, Liver Cirrhosis
The Role of the Kidneys and Liver in the Elimination of Glucagon
The study aims to evaluate the kinetics and effect of glucagon in patients with chronic kidney disease and liver cirrhosis and matched healthy subjects, respectively.
- Conditions
- Chronic Kidney Diseases, Liver Cirrhosis, Hyperglucagonemia
- Trial name
- MCR_EndCir (NCT05056584)
- Testing
- Glucagon infusion, Primed tracer infusion
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Clinical Trial, Phase I, Pharmacokinetics
Rogaratinib (BAY1163877) Human Mass Balance Study
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 200 mg dose of [14C]rogaratinib given as a solution.
- Trial name
- NCT03484585
- Testing
- Rogaratinib (BAY1163877)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Wilson Disease
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain.
- Trial name
- VARCUWIC (NCT06430359)
- Testing
- urine and blood test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Healthy
Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations
Physicians know that their patients can react differently to the same medical treatment: for some of them, the drug will prove inefficient, whereas for others it might provoke side-effects, sometimes rather serious.
- Trial name
- NCT02789527
- Testing
- Phenotyping, Genotyping
- Where
- 4 sites in Czechia, Ethiopia and 2 more
- Volunteers
- 367 people, healthy volunteers welcome
- Sponsor
- Estella S. Poloni
Healthy
Food Effect and Mass Balance Study of XZP-3621 Tablets
This is a single-center, open-label, single-dose phase I study, the study is divided into two stages. The stage 1 is to investigate the absorption, metabolism and excretion of XZP-3621 tablets in healthy Chinese subjects.
- Trial name
- NCT05034120
- Testing
- XZP-3621
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Healthy Subjects
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
The primary objectives of the study are: to characterize the primary route(s) of elimination of [14C]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants…
- Trial name
- NCT05578859
- Testing
- AMG 510
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Amgen
Hyperphagia, Prader-Willi Syndrome
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.
- Trial name
- HERO (NCT06828861)
- Testing
- ARD-101
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 68 people
- Sponsor
- Aardvark Therapeutics, Inc.
Intestinal Disorders, Bowel Diseases, Inflammatory
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects.
- Trial name
- NCT03408470
- Testing
- TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy Volunteers
A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)
This is a Phase 1, open-label, nonrandomized, single-dose human, absorption, metabolism, and excretion study of [14C]-Fosgonimeton
- Trial name
- NCT05511558
- Testing
- [14C]-Fosgonimeton
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- LeonaBio
Respiratory Syncytial Virus Infections
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.
- Trial name
- NCT02231671
- Testing
- ALS-008176, ALS-008112
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Healthy Subject
Human Mass Balance Study of HMS5552 in Healthy Subjects
This is an open-label, single center, 1-period study in healthy adult male subjects to assess absorption, metabolism, and excretion of HMS5552 after a single oral administration of 50 mg (90 μCi) of [14C]-HMS5552.
- Trial name
- NCT03158506
- Testing
- HMS5552
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
Advanced Solid Tumors
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the metabolism and elimination of carbon-14 labeled eribulin acetate (14C-eribulin) in patients with advanced solid tumors.
- Trial name
- NCT00908908
- Testing
- eribulin
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.